396 related articles for article (PubMed ID: 24982311)
21. Are thiopurines always contraindicated after thiopurine-induced pancreatitis in inflammatory bowel disease?
Ledder OD; Lemberg DA; Ooi CY; Day AS
J Pediatr Gastroenterol Nutr; 2013 Nov; 57(5):583-6. PubMed ID: 23783022
[TBL] [Abstract][Full Text] [Related]
22. Drug-induced acute pancreatitis due to medications used for inflammatory bowel disease: A VigiBase pharmacovigilance database study.
Lee AA; Gupta S; Labban M; Cao FT; Trinh QD; McNabb-Baltar J
Pancreatology; 2023 Sep; 23(6):569-573. PubMed ID: 37302896
[TBL] [Abstract][Full Text] [Related]
23. Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system.
Kip KE; Swoger JM; Grandinetti LM; Barrie AM; Greer JB; Regueiro MD
Inflamm Bowel Dis; 2013 May; 19(6):1164-72. PubMed ID: 23518804
[TBL] [Abstract][Full Text] [Related]
24. Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease?: an audit of adverse events and outcome.
Shah JA; Edwards CM; Probert CS
Eur J Gastroenterol Hepatol; 2008 Mar; 20(3):169-73. PubMed ID: 18301295
[TBL] [Abstract][Full Text] [Related]
25. Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis.
Mozaffari S; Abdolghaffari AH; Nikfar S; Abdollahi M
Hum Exp Toxicol; 2015 May; 34(5):445-59. PubMed ID: 25378092
[TBL] [Abstract][Full Text] [Related]
26. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease.
van Schaik FD; van Oijen MG; Smeets HM; van der Heijden GJ; Siersema PD; Oldenburg B
Gut; 2012 Feb; 61(2):235-40. PubMed ID: 21602529
[TBL] [Abstract][Full Text] [Related]
27. Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases.
Kirchgesner J; Lemaitre M; Carrat F; Zureik M; Carbonnel F; Dray-Spira R
Gastroenterology; 2018 Aug; 155(2):337-346.e10. PubMed ID: 29655835
[TBL] [Abstract][Full Text] [Related]
28. Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease.
Casanova MJ; Chaparro M; Domènech E; Barreiro-de Acosta M; Bermejo F; Iglesias E; Gomollón F; Rodrigo L; Calvet X; Esteve M; García-Planella E; García-López S; Taxonera C; Calvo M; López M; Ginard D; Gómez-García M; Garrido E; Pérez-Calle JL; Beltrán B; Piqueras M; Saro C; Botella B; Dueñas C; Ponferrada A; Mañosa M; García-Sánchez V; Maté J; Gisbert JP
Am J Gastroenterol; 2013 Mar; 108(3):433-40. PubMed ID: 23318480
[TBL] [Abstract][Full Text] [Related]
29. Treatment-based risk stratification of infections in inflammatory bowel disease: A comparison between anti-tumor necrosis factor-α and nonbiological exposure in real-world setting.
Imperatore N; Foggia M; Patturelli M; Rispo A; Calabrese G; Testa A; Pellegrini L; Tosone G; Di Luna I; Nardone OM; Ricciolino S; Castiglione F
J Gastroenterol Hepatol; 2021 Jul; 36(7):1859-1868. PubMed ID: 33283312
[TBL] [Abstract][Full Text] [Related]
30. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease.
Akbari M; Shah S; Velayos FS; Mahadevan U; Cheifetz AS
Inflamm Bowel Dis; 2013 Jan; 19(1):15-22. PubMed ID: 22434610
[TBL] [Abstract][Full Text] [Related]
31. Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19.
Izadi Z; Brenner EJ; Mahil SK; Dand N; Yiu ZZN; Yates M; Ungaro RC; Zhang X; Agrawal M; Colombel JF; Gianfrancesco MA; Hyrich KL; Strangfeld A; Carmona L; Mateus EF; Lawson-Tovey S; Klingberg E; Cuomo G; Caprioli M; Cruz-Machado AR; Mazeda Pereira AC; Hasseli R; Pfeil A; Lorenz HM; Hoyer BF; Trupin L; Rush S; Katz P; Schmajuk G; Jacobsohn L; Seet AM; Al Emadi S; Wise L; Gilbert EL; Duarte-García A; Valenzuela-Almada MO; Isnardi CA; Quintana R; Soriano ER; Hsu TY; D'Silva KM; Sparks JA; Patel NJ; Xavier RM; Marques CDL; Kakehasi AM; Flipo RM; Claudepierre P; Cantagrel A; Goupille P; Wallace ZS; Bhana S; Costello W; Grainger R; Hausmann JS; Liew JW; Sirotich E; Sufka P; Robinson PC; Machado PM; Griffiths CEM; Barker JN; Smith CH; Yazdany J; Kappelman MD; ;
JAMA Netw Open; 2021 Oct; 4(10):e2129639. PubMed ID: 34661663
[TBL] [Abstract][Full Text] [Related]
32. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease.
Ansari A; Patel N; Sanderson J; O'Donohue J; Duley JA; Florin TH
Aliment Pharmacol Ther; 2010 Mar; 31(6):640-7. PubMed ID: 20015102
[TBL] [Abstract][Full Text] [Related]
33. NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study.
Kakuta Y; Kawai Y; Okamoto D; Takagawa T; Ikeya K; Sakuraba H; Nishida A; Nakagawa S; Miura M; Toyonaga T; Onodera K; Shinozaki M; Ishiguro Y; Mizuno S; Takahara M; Yanai S; Hokari R; Nakagawa T; Araki H; Motoya S; Naito T; Moroi R; Shiga H; Endo K; Kobayashi T; Naganuma M; Hiraoka S; Matsumoto T; Nakamura S; Nakase H; Hisamatsu T; Sasaki M; Hanai H; Andoh A; Nagasaki M; Kinouchi Y; Shimosegawa T; Masamune A; Suzuki Y;
J Gastroenterol; 2018 Sep; 53(9):1065-1078. PubMed ID: 29923122
[TBL] [Abstract][Full Text] [Related]
34. Timing of Thiopurine or Anti-TNF Initiation Is Associated with the Risk of Major Abdominal Surgery in Crohn's Disease: A Retrospective Cohort Study.
González-Lama Y; Suárez C; González-Partida I; Calvo M; Matallana V; de la Revilla J; Magaz M; Bernardo C; Agudo B; Ibarrola P; Relea L; Arévalo J; Vera MI; Abreu L
J Crohns Colitis; 2016 Jan; 10(1):55-60. PubMed ID: 26520164
[TBL] [Abstract][Full Text] [Related]
35. State-of-the-art: Immunosuppression and biologic therapy.
Sandborn WJ
Dig Dis; 2010; 28(3):536-42. PubMed ID: 20926883
[TBL] [Abstract][Full Text] [Related]
36. Thiopurine therapy in inflammatory bowel disease.
Ha C; Dassopoulos T
Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):575-88. PubMed ID: 20932143
[TBL] [Abstract][Full Text] [Related]
37. Listeria monocytogenes infection in patients with inflammatory bowel diseases receiving anti-tumor necrosis factor therapy.
Ramos JM; García-Sepulcre MF; Masiá M; Brotons A; Grau MC; Gutiérrez F
Rev Esp Enferm Dig; 2010 Oct; 102(10):614-6. PubMed ID: 21039077
[No Abstract] [Full Text] [Related]
38. Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease.
Cao Q; Zhu Q; Shang Y; Gao M; Si J
Digestion; 2009; 79(1):58-63. PubMed ID: 19252404
[TBL] [Abstract][Full Text] [Related]
39. HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease.
Wilson A; Jansen LE; Rose RV; Gregor JC; Ponich T; Chande N; Khanna R; Yan B; Jairath V; Khanna N; Sey M; Beaton M; McIntosh K; Teft WA; Kim RB
Aliment Pharmacol Ther; 2018 Mar; 47(5):615-620. PubMed ID: 29270995
[TBL] [Abstract][Full Text] [Related]
40. Comparative tolerability of treatments for inflammatory bowel disease.
Stein RB; Hanauer SB
Drug Saf; 2000 Nov; 23(5):429-48. PubMed ID: 11085348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]